Serum levels of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological diseases.

@article{Torre1991SerumLO,
  title={Serum levels of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological diseases.},
  author={Gian Carlo Torre and R Rembado and Valentina Barbetti and Giacomo Vigliercio and Marc Foglia and Antonio Calabrese and Francesco P. Corongiu},
  journal={Scandinavian journal of clinical and laboratory investigation. Supplementum},
  year={1991},
  volume={207},
  pages={15-8}
}
The behavior of tumor-associated trypsin inhibitor (TATI) as a marker for gynecological cancer was studied in a control population and in patients with different benign and malignant diseases. When a cut-off level of 21.4 micrograms/l was used the specificity was 100% in patients with benign diseases. The sensitivity in patients with malignant tumors was low for cervical and corpus cancer, 13% and 14%, respectively, whereas it was 33% in all the ovarian malignant tumors, reaching 60% in the… CONTINUE READING

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…